CTOs on the Move

Ginkgo Bioworks

www.ginkgobioworks.com

 
At Ginkgo Bioworks we are expanding the role of biology in our world.Nature`s biodiversity holds answers to challenges in health, energy, food, materials, and more. Organism Engineers at Ginkgo learn from Nature to develop new organisms that replace technology with biology.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Michael Kuchinskas
VP of Protein Engineering Profile
Christopher Mellen
Director of Information Security Profile

Funding

Ginkgo Bioworks raised $45M on 07/23/2015
Ginkgo Bioworks raised $100M on 06/08/2016
Ginkgo Bioworks raised $275M on 12/14/2017
Ginkgo Bioworks raised $290M on 09/19/2019

Similar Companies

United States Biological Corporation

United States Biological Corporation is a Marblehead, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Church Street Health Management

"Our company`s promise is in our name - CSHM - Committed to Smiles and a Healthy Mouth. Our mission is to ensure access to quality, professional dental care for low-income, underserved families and those seeking comprehensive care. Our dental centers are creating access to dental health services for these families – and especially their children – who are often least able to afford care."

Fujifilm Diosynth Biotechnologies

As a CDMO our focus is to combine technical leadership in cell culture, microbial fermentation and viral vectors with world class cGMP manufacturing facilities to advance tomorrow`s medicines. For over 25 years our focus has been on supporting our customers with the development and manufacture of recombinant proteins, viral vaccines and gene therapies.

OmniAb

OmniAb is a leading edge antibody discovery company that provides access to diverse antibody repertoires and high throughput screening technologies. They specialize in therapeutic antibody discovery using chickens as immunization hosts, which allows fo...

Exicure

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.